# A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)

> **NCT03669393** · PHASE2 · COMPLETED · sponsor: **ThromboGenics** · enrollment: 8 (actual)

## Conditions studied

- Retinal Telangiectasis
- Idiopathic Juxtafoveal Retinal Telangiectasia

## Interventions

- **DRUG:** THR-317 8mg

## Key facts

- **NCT ID:** NCT03669393
- **Lead sponsor:** ThromboGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-18
- **Primary completion:** 2019-11-22
- **Final completion:** 2019-11-22
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03669393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03669393, "A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03669393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*